• Hanssens S, Luyten R, Watthy C, Fontaine C, Decoster L, Baillon C, Trullemans F, Cortoos A, De Grève J. Evaluation of a comprehensive rehabilitation program for post-treatment patients with cancer. Hanssens S, Luyten R, Watthy C, Fontaine C, Decoster L, Baillon C, Trullemans F, Cortoos A, De Grève J. Oncol Nurs Forum. 2011 Nov 1;38(6):E418-24.
• Van Bael K, Aerts M, de Ridder M, de Gréve J, Delvaux G, Neyns B. Durable remission of inoperable liver metastasis from rectal cancer after hepatic arterial infusion of oxaliplatin and 5-fluorouracil in combination with intravenous cetuximab. Curr Oncol. 2011 Oct;18(5):e256-9.
• Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res. 2011 Mar;4(2):40-4
• Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A, De Greve J. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2011 Jul;103(3):491-501. Epub 2010 Sep 25
• Leyder M, Laubach M, Breugelmans M, Keymolen K, De Greve J, Foulon W. Specific congenital malformations after exposure to cyclophosphamide, epirubicin and 5-fluorouracil during the first trimester of pregnancy. Gynecol Obstet Invest. 2011;71(2):141-4. Epub 2010 Dec 14
• Schallier D, Decoster L, de Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res. 2011 May;31(5):1753-5
• Mazzeo F, Duck L, Joosens E, Dirix L, Focan C, Forget F, De Geest S, Muermans K, VAN Lierde MA, Macdonald K, Abraham I, De Grève J. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res. 2011 Apr;31(4):1407-9